Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Long-Term Debt Repayments (2016 - 2021)

Pharma-Bio Serv's Long-Term Debt Repayments history spans 12 years, with the latest figure at $64228.0 for Q2 2021.

  • For Q2 2021, Long-Term Debt Repayments rose 2244.94% year-over-year to $64228.0; the TTM value through Apr 2022 reached $64228.0, down 11.61%, while the annual FY2020 figure was $11030.0, 83.7% down from the prior year.
  • Long-Term Debt Repayments reached $64228.0 in Q2 2021 per PBSV's latest filing, up from $2851.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $64228.0 in Q2 2021 to a low of $2631.0 in Q3 2019.
  • Average Long-Term Debt Repayments over 5 years is $11967.9, with a median of $3306.5 recorded in 2018.
  • Peak YoY movement for Long-Term Debt Repayments: plummeted 95.36% in 2020, then soared 2244.94% in 2021.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $3263.0 in 2017, then increased by 22.25% to $3989.0 in 2018, then tumbled by 33.19% to $2665.0 in 2019, then increased by 5.55% to $2813.0 in 2020, then soared by 2183.26% to $64228.0 in 2021.
  • Per Business Quant, the three most recent readings for PBSV's Long-Term Debt Repayments are $64228.0 (Q2 2021), $2851.0 (Q1 2021), and $2813.0 (Q4 2020).